Ovarian CanceRx

Ovarian CanceRx Leadership

Beth Y. Karlan, MD

Director, Cancer Population Genetics
UCLA, Jonsson Comprehensive Cancer Center

Chair, Steering Committee

Ursula A. Matulonis, MD

Chief, Division of Gynecologic Oncology
Dana-Farber Cancer Institute
Professor of Medicine, Harvard Medical School

Chair, Arm Selection Committee

Lynda D. Roman, MD

Associate Professor of Obstetrics and Gynecology
Division Chief, Gynecologic Oncology
Keck School of Medicine of USC

Chair, Clinical Leadership

Anil K. Sood, MD

Professor and Vice-Chair for Translational Research in the Departments of Gynecologic Oncology and Cancer Biology
The University of Texas MD Anderson Cancer Center

Chair, Translational Leadership

Andrew W. Lo, PhD

Charles E. and Susan T. Harris Professor, Finance
Director, Laboratory for Financial Engineering
MIT Sloan School of Management

Chair, Financial Innovation and Strategy

Kathleen Moore, MD, MS

Professor of Gynecologic Oncology, Department of Obstetrics and Gynecology
University of Oklahoma Health Sciences Center

Co-Chair, Arm Selection Committee

David M. O’Malley, MD

Professor, Department of Obstetrics and Gynecology
Director, Division of Gynecologic Oncology
Director, Clinical Research
The Ohio State University Comprehensive Cancer Center, The James

Co-Chair, Clinical Leadership

Kunle Odunsi, MD, PhD

Director, Comprehensive Cancer Center
Biological Sciences Division Dean for Oncology
University of Chicago Medicine

Co-Chair, Translational Leadership

5

Ovarian cancer accounts for 5% of all cancer death in women

90

Cases detected early have a +90% survival rate after 5 years

45

Women with BRCA1 gene mutation have a 45% lifetime risk of ovarian cancer

Rapid. Adaptive. Needed.

In the Fight Against Advanced Ovarian Cancer.

Partner With Us